Aprea Therapeutics, Inc.

NasdaqCM:APRE Stock Report

Market Cap: US$8.9m

Aprea Therapeutics Management

Management criteria checks 4/4

Aprea Therapeutics' CEO is Oren Gilad, appointed in Jan 2011, has a tenure of 15.42 years. total yearly compensation is $657.26K, comprised of 90.5% salary and 9.5% bonuses, including company stock and options. directly owns 3.04% of the company’s shares, worth $270.10K. The average tenure of the management team and the board of directors is 4.4 years and 5 years respectively.

Key information

Oren Gilad

Chief executive officer

US$657.3k

Total compensation

CEO salary percentage90.51%
CEO tenure15.4yrs
CEO ownership3.0%
Management average tenure4.4yrs
Board average tenure5yrs

Recent management updates

Recent updates

Analysis Article • Aug 06

Is Aprea Therapeutics (NASDAQ:APRE) In A Good Position To Deliver On Growth Plans?

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Analysis Article • Jan 10

We're Keeping An Eye On Aprea Therapeutics' (NASDAQ:APRE) Cash Burn Rate

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

CEO Compensation Analysis

How has Oren Gilad's remuneration changed compared to Aprea Therapeutics's earnings?
DateTotal CompensationSalaryCompany Earnings
Mar 31 2026n/an/a

-US$12m

Dec 31 2025US$657kUS$595k

-US$13m

Sep 30 2025n/an/a

-US$13m

Jun 30 2025n/an/a

-US$14m

Mar 31 2025n/an/a

-US$14m

Dec 31 2024US$760kUS$572k

-US$13m

Sep 30 2024n/an/a

-US$14m

Jun 30 2024n/an/a

-US$13m

Mar 31 2024n/an/a

-US$13m

Dec 31 2023US$877kUS$550k

-US$14m

Sep 30 2023n/an/a

-US$13m

Jun 30 2023n/an/a

-US$14m

Mar 31 2023n/an/a

-US$109m

Dec 31 2022US$753kUS$324k

-US$113m

Compensation vs Market: Oren's total compensation ($USD657.26K) is about average for companies of similar size in the US market ($USD641.77K).

Compensation vs Earnings: Oren's compensation has been consistent with company performance over the past year.

CEO

Oren Gilad (58 yo)

15.4yrs
Tenure
US$657,259
Compensation

Dr. Oren Gilad, Ph.D. is Co-Founder of Aprea Therapeutics, Inc (formerly known as Atrin Pharmaceuticals LLC) since 2011 and serves as its Chief Executive Officer since July 2022. Dr. Gilad serves as Presid...

Leadership Team

NamePositionTenureCompensationOwnership
Oren Gilad
Co-Founder15.4yrsUS$657.26k3.04%
$ 270.1k
John Hamill
Senior VP3.4yrsUS$490.65k0.23%
$ 20.6k
Lars Abrahmsen
Senior VP & Chief Scientific Officer11.7yrsno datano data
Brian Wiley
Senior Vice President of Corporate Development & Strategy2.6yrsno datano data
Michel Afargan
Head of Pharmacology Development8.4yrsno datano data
Ze'ev Weiss
Chief Business Advisor4.1yrsno datano data
Eugene Kennedy
Chief Medical Advisorless than a yearno datano data
Andrea Epstein
Controller4.8yrsno datano data
4.4yrs
Average Tenure
60yo
Average Age

Experienced Management: APRE's management team is considered experienced (4.4 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Oren Gilad
Co-Founder4.1yrsUS$657.26k3.04%
$ 270.1k
Bernd Seizinger
Independent Director11.4yrsUS$66.75k0.36%
$ 32.4k
John Henneman
Independent Director6.8yrsUS$66.25k0.068%
$ 6.0k
Rifat Pamukcu
Independent Director4.1yrsUS$61.25k0.15%
$ 12.9k
Marc Duey
Independent Director4.1yrsUS$53.25k2.13%
$ 189.6k
Geoffrey Shapiro
Scientific & Clinical Advisory Board Member7.4yrsno datano data
Richard Peters
Independent Chairperson of the Board6yrsUS$88.25k0.0086%
$ 763.1
Eric Brown
Member of Scientific Advisory Boardno datano datano data
Michael Grissinger
Independent Director4.1yrsUS$62.75k0.0067%
$ 592.6
Timothy A. Yap
Scientific & Clinical Advisory Board Memberno datano datano data
Karen Knudsen
Scientific & Clinical Advisory Boardno datano datano data
Zvi Fridlender
Scientific & Clinical Advisory Board Memberno datano datano data
5.0yrs
Average Tenure
64yo
Average Age

Experienced Board: APRE's board of directors are considered experienced (5 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/06/07 20:00
End of Day Share Price 2026/06/05 00:00
Earnings2026/03/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Aprea Therapeutics, Inc. is covered by 5 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Esther Lannie HongBerenberg
Joseph PantginisH.C. Wainwright & Co.
Jason McCarthyMaxim Group